1. - Cash and cash equivalents totaled approximately $306 million at December 31, 2019 -

    - Positive AURORA Phase 3 results with voclosporin enabling an NDA submission for the treatment of lupus nephritis ("LN") by the end of the second quarter 2020 -

    - Continued build out of a top-tier commercial team, highlighted by the appointment of Max Colao, Chief Commercial Officer, focused on launch activities -

    - AUDREY Phase2/3 Dry Eye Study remains on-track with results anticipated during the second half of 2020 -

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company") today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless specified otherwise, are expressed in U.S…

    View Full Article
  2. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after the markets close. Aurinia's management team will host a conference call to discuss the Company's financial results and to provide a general business update.

    The conference call and webcast is scheduled for March 5, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia's…

    View Full Article
  3. - Industry veteran, Max Colao, appointed Chief Commercial Officer -

    - Recruited four seasoned executives with expertise across critical commercial functions -

    - Rapidly preparing for the potential commercialization of voclosporin during the first half of 2021 -

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Max Colao to the newly created position of Chief Commercial Officer. In addition, Aurinia has recruited an experienced team of leaders across key commercial functions including sales, marketing, market access, and commercial operations.

    "This is a very exciting…

    View Full Article
  4. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.

    The presentation will be webcast live and accessible via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the Company website following the event.

    About Aurinia

    Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical…

    View Full Article
  5. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters' option to purchase additional common shares (the "Offering"). The shares were sold at a public offering price of US$15.00 per share. The gross offering proceeds to the Company from this Offering are approximately US$191.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

    Jefferies LLC and SVB Leerink LLC…

    View Full Article